GlassScriptPhysician profile
Sarah C Stierman
NPI 1649447731
$29,320.27
in general payments reported to CMS, 2019-2025
33 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,479 · 2021: $3,561 · 2022: $1,834 · 2023: $1,364 · 2024: $1,601 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,303 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,302.73 |
| Education | $220.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,458.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $6,906.75 | 2019-2025 | |
| Amgen INC. | $4,714.10 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $2,240.42 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Allergan, INC. | $2,028.84 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $792.71 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $607.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $583.99 | 2019-2025 | |
| Ucb, INC. | $485.08 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $299.22 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $284.18 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $263.89 | 2019-2025 | Winlevi, Absorica Ld |
| Janssen Scientific Affairs, LLC | $257.56 | 2019-2022 | |
| Incyte Corporation | $206.86 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $194.80 | 2021-2025 | Nemluvio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $172.03 | 2019-2025 | Adbry, Spevigo |
| Lilly USA, LLC | $170.67 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Almirall LLC | $152.82 | 2019-2021 | |
| Genentech USA, INC. | $96.64 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.83 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $68.40 | 2023 | |
| Dermavant Sciences, INC. | $45.16 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $36.14 | 2019-2022 | |
| Sientra, INC. | $22.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.47 | 2019 | |
| Aclaris Therapeutics, INC. | $19.17 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.51 | 2021 | |
| Epi Health, LLC | $17.88 | 2020 | |
| Dusa Pharmaceuticals, INC. | $17.59 | 2019 | |
| Prugen, INC. Pharmaceuticals | $17.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2023 | Spevigo |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Journey Medical Corporation | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Stierman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.